Allergy

Researchers are evaluating the effect of starting Airsupra inhaler treatment in emergency departments (ED) on reducing acute asthma recurrence and other related outcomes over three months. The study focuses on adults aged 18 to 54 who visit the ED for asthma exacerbations and are discharged with a short course of systemic corticosteroids. This trial is a cluster randomized, open-label study comparing Airsupra use to usual care across multiple centers. Participants will be assigned by site to either receive usual care or Airsupra as their rescue inhaler along with corticosteroids. Airsupra dosing is as needed, with up to six doses per day. The study will run for about four to five months of enrollment per site, with follow-up assessments conducted at approximately 3, 6, and 12 weeks after the ED discharge to monitor asthma control, relapse, and recurrence. During the study, patients will complete interviews and chart reviews in the ED, and follow-up will include telephone or text contact to assess their clinical status and medication use. Medical records from before and after enrollment will be reviewed to identify asthma exacerbations. The main outcome is asthma recurrence within three months, with asthma control and early relapse also measured. Participants’ data will be securely managed throughout the study period, which extends up to 12 weeks post-ED visit.

Researchers are evaluating whether the supplement 5-hydroxytryptophan (5HTP) can improve breathing and reduce anxiety symptoms in children with mild to moderate allergic asthma. This phase 2 study aims to test if 5HTP reduces allergic lung responses, improves lung function measured by Forced Expiratory Volume at one second (FEV1), lowers blood eosinophil counts, and decreases anxiety and depression symptoms. The study is sponsored by Indiana University. Participants will receive either 5HTP or a placebo during two 28-day dosing periods separated by a 3-week washout phase. The 5HTP dose is based on weight: 50mg twice daily for those under 100 lbs, and 100mg twice daily for those over 100 lbs. The study uses a randomized, triple-blind crossover design, meaning participants switch from one treatment to the other during the study. Over about 12 weeks, participants will attend five study visits where lung function tests, blood samples to measure eosinophils, and anxiety/depression questionnaires will be completed. Researchers will monitor changes in lung function, blood markers, and mental health symptoms to evaluate the effects of 5HTP. Safety assessments will ensure participant well-being throughout the study period.

Researchers are observing the safety and effectiveness of Atectura inhalation capsule in people aged 12 to 100 years with asthma over a 24-week period. This non-interventional, open-label study takes place across multiple centers and follows routine clinical practice without additional diagnostic or monitoring procedures beyond standard care. The study aims to gather real-world data on the use of Atectura as prescribed under approved labeling in Korea. Participants will use one of three doses of Atectura inhalation capsule delivered via Breezhaler: 150/80 µg, 150/160 µg, or 150/320 µg of indacaterol acetate/mometasone furoate. Treatments are prescribed by physicians according to routine care, and patients who have already started Atectura before joining the study will be included. No randomization or placebo control is involved since this is an observational study. During the study, researchers will track adverse events and serious adverse events over 24 weeks to evaluate safety. Lung function changes will be measured by trough FEV1 at baseline and week 12, along with asthma control using the ACT score. Effectiveness will also be assessed by investigators at week 12. Patient data on drug reactions and lung function changes will be collected to better understand treatment impact. The study runs until December 2026 and involves regular clinical assessments without extra tests beyond standard asthma care.

Researchers are observing adult patients with asthma who have been prescribed Enerzair inhalation capsules to evaluate the safety and effectiveness of this treatment over a 24-week period in real-world clinical settings. This study is open-label, prospective, multicenter, and single-arm, designed to monitor outcomes without additional interventions beyond routine care. Participants will receive one of two doses of Enerzair via Breezhaler, either 150/50/80 micrograms or 150/50/160 micrograms, as prescribed according to approved labeling in Korea. No extra diagnostic or monitoring procedures beyond standard clinical practice will be conducted during the study. Throughout the study, participants will be monitored for adverse events and serious adverse events for up to 24 weeks. Researchers will also assess lung function using trough FEV1 measurements and asthma control using the ACT score at baseline and week 12. Effectiveness will be evaluated by investigator assessment, and patient characteristics related to safety and efficacy outcomes will be recorded. The study involves collection of data without altering prescribed treatment and ensures ongoing observation in a routine care environment.

Researchers are evaluating the safety and effectiveness of SHR-1819 injection in treating adults with seasonal allergic rhinitis, a condition causing nasal allergy symptoms during pollen seasons. This phase II study is randomized, double-blind, and placebo-controlled, aiming to understand how the drug affects nasal symptoms and its behavior in the body. Participants are randomly assigned to receive one of two doses of SHR-1819 injection or a placebo. The study includes a treatment period lasting up to 4 weeks, where the impact on nasal symptoms is closely monitored. The trial also tracks safety by recording any adverse events for up to 12 weeks. Throughout the study, participants will complete daily symptom diaries and undergo assessments to measure changes in nasal symptoms using a total nasal symptom score. Researchers will collect data on how the drug is processed in the body and monitor participants' safety. The total participation time may extend beyond the treatment period to capture all necessary outcome and safety information.

Dentin hypersensitivity (DH) causes sharp, short pain from exposed dentin triggered by chemicals, temperature, or touch. It commonly affects older adults and varies widely in prevalence. This research evaluates the effectiveness of Casein phosphopeptide paste (CPP-ACP) alone or combined with a diode laser called Lasotronix in treating DH, as limited studies have explored this combination. The study involves four groups: one receiving CPP-ACP paste application only, one receiving diode laser therapy only, a third receiving both CPP-ACP and laser treatments, and a control group with no treatment. Lasotronix uses a 635nm wavelength laser designed for safe and effective bio-stimulation and photo-disinfection, while CPP-ACP paste aims to reduce pain by managing dentin sensitivity. Participants aged 25 to 65 with at least one sensitive, vital tooth without decay or defective restoration will be involved. They will undergo treatment and follow-up to assess dentin hypersensitivity over three months. Researchers will monitor pain levels and treatment effects, ensuring safety and adherence to the study protocol throughout the trial period.

This research focuses on chronic inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and interstitial lung diseases (ILD). These conditions involve inflammation and changes in lung structure with a wide range of symptoms and features. The study aims to analyze various characteristics including clinical, biological, and microbiological traits, as well as respiratory exposures and mechanisms related to airway inflammation, to better understand these diseases beyond their initial diagnosis. The study is a prospective cohort conducted at the University Hospital of Reims, France, including adults aged 18 and older diagnosed with the listed respiratory diseases or healthy volunteers as controls. Participants will be followed over a 10-year period with data collected at inclusion and follow-up visits, while controls will only provide data at inclusion. No specific treatments are given as part of the study; care continues as usual. Throughout the study, information such as demographics, disease history, lung function tests, CT scans, and respiratory sample analyses will be collected and stored in an anonymous database. Researchers will use statistical and machine learning methods to identify patient groups with similar disease patterns and predict disease progression and treatment responses. The study is planned to start in September 2025 with a recruitment period lasting five years and follow-up for a decade thereafter.

Asthma is a common condition marked by breathing difficulties, coughing, and wheezing. Diagnosing asthma relies on identifying airflow obstruction, airway sensitivity, and inflammation, but international guidelines vary in their criteria. This research evaluates how well these guidelines agree in diagnosing asthma and explores additional lung function tests like impulse oscillometry (IOS), which is not commonly included in guidelines but available at the Portsmouth lung function service. The study involves analyzing routine lung function data from patients attending the severe asthma service at Queen Alexandra Hospital in Portsmouth. It compares standard diagnostic tests recommended by international guidelines with IOS, a simple, non-invasive test measuring lung function. The goal is to see if IOS can improve the accuracy and ease of diagnosing asthma in adults. Participants' lung function data will be reviewed using both guideline-based and additional criteria, focusing on how well each method identifies asthma. Outcomes include scores based on international asthma guidelines and numbers related to non-guideline lung function tests, assessed about four weeks after recruitment. The study uses an opt-out consent process and aims to provide insights that may enhance asthma diagnosis and management.

This research observes children who took part in the TEMPO clinical trial during their first year of life to understand if their early feeding patterns affect the development of allergies or infections in childhood. The study follows these children up to 7.5 years to gather information on allergic symptoms, infections, and related medical care. It is an observational study without additional treatments or interventions. Participants complete self-administered digital questionnaires every three months using a smartphone, tablet, or computer. These questionnaires collect data on allergies, infections, medication use, medical device use, hospitalizations, and emergency room visits. The study is entirely virtual and decentralized, allowing families to participate remotely. Throughout the study, parents provide information via regular online questionnaires, helping researchers track their child's health over time. The main measurements include parent-reported symptoms, medication or device use, and healthcare visits related to allergies and infections. The study runs until March 2029 and includes children aged 3 to 10 years who completed the original TEMPO study.

Researchers are studying allergic asthma in children aged 6 to 17 years who identify as African American/Black or Caucasian/White. This randomized, double-blind, placebo-controlled crossover trial evaluates whether the antihistamine Levocetirizine (LTZ) improves asthma control in children with different histamine response types measured by Histamine Lontophoresis with Laser Doppler monitoring (HILD). The study aims to develop a biomarker that predicts therapeutic response and improve treatment decisions in pediatric asthma. Participants will be randomly assigned to receive either Levocetirizine dihydrochloride oral solution (2.5mg for children 6-11 years and 5mg for children over 11) or a placebo, both added to their current asthma therapy. The study includes screening, treatment periods, and assessments at baseline, 6 weeks after starting treatment, and after crossover to the alternate treatment. Each arm lasts approximately 6 weeks, with a total participation time of around 17 weeks. Children will undergo asthma control assessments using the Asthma Control Test (ACT) or Child-Asthma Control Test (C-ACT) depending on age. Other measures include asthma impairment, risk, and quality of life evaluations. Blood draws and HILD testing will be performed to monitor histamine response. The primary outcome is the change in asthma control after 6 weeks of treatment. Safety and adherence will be monitored throughout the study.